STOCK TITAN

[SCHEDULE 13G/A] Evotec SE Amended Passive Investment Disclosure

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Novo Holdings A/S now reports no ownership in Evotec SE. In this amended Schedule 13G/A, the Danish investment firm states it beneficially owns 0 ordinary shares of Evotec SE, representing 0.0% of the class, as of 12/31/2025.

The filing shows Novo Holdings has no sole or shared voting power and no sole or shared dispositive power over any Evotec shares. It confirms that Novo Holdings’ holdings are now 5 percent or less of the class, meaning it is no longer a significant beneficial owner under U.S. disclosure rules.

Positive

  • None.

Negative

  • None.

Insights

Novo Holdings no longer counts as a significant Evotec shareholder under U.S. rules.

The filing shows Novo Holdings A/S reporting beneficial ownership of 0 Evotec SE ordinary shares, or 0.0% of the class, as of 12/31/2025. It lists zero sole or shared voting and dispositive power, indicating no remaining reportable stake.

This Schedule 13G/A matters because such forms are required when a holder previously above disclosure thresholds changes its position. The amendment formally records that Novo Holdings’ interest has fallen to 5 percent or less, removing it from the ranks of large reported shareholders under these U.S. reporting standards.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Novo Holdings A/S
Signature:Barbara Fiorini
Name/Title:Barbara Fiorini, General Counsel, Finance & Operations
Date:02/17/2026
Evotec Se

OTC:EVOTF

EVOTF Rankings

EVOTF Latest News

EVOTF Stock Data

1.25B
151.11M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Germany
Hamburg